Single low-dose lipopolysaccharide preconditioning: neuroprotective against axonal injury and modulates glial cells
Neuroimmunology and Neuroinflammation · 20.01.2017 · 4 (1) · 6
DOI: 10.20517/2347-8659.2016.40 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuroimmunology and Neuroinflammation, online erschienen am 20.01.2017. Verfasst von Ryan C Turner und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, West Virginia University, School of Medicine, Morgantown, WV 26506, USA; Center for Neuroscience, West Virginia Universit…. Die Arbeit wurde bisher 44-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
AIM: Over 7 million traumatic brain injuries (TBI) are reported each year in the United States. However, treatments and neuroprotection following TBI are limited because secondary injury cascades are poorly understood. Lipopolysaccharide (LPS) administration before controlled cortical impact can contribute to neuroprotection. However, the underlying mechanisms and whether LPS preconditioning confers neuroprotection against closed-head injuries remains unclear. METHODS: The authors hypothesized that preconditioning with a low dose of LPS (0.2 mg/kg) would regulate glial reactivity and protect against diffuse axonal injury induced by weight drop. LPS was administered 7 days prior to TBI. LPS administration reduced locomotion, which recovered completely by time of injury. RESULTS: LPS preconditioning significantly reduced the post-injury gliosis response near the corpus callosum, possibly by downregulating the oncostatin M receptor. These novel findings demonstrate a protective role of LPS preconditioning against diffuse axonal injury. LPS preconditioning successfully prevented neurodegeneration near the corpus callosum, as measured by fluorojade B. CONCLUSION: Further work is required to elucidate whether LPS preconditioning confers long-term protection against behavioral deficits and to elucidate the biochemical mechanisms responsible for LPS-induced neuroprotective effects.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, West Virginia University, School of Medicine, Morgantown, WV 26506, USA; Center for Neuroscience, West Virginia University, School of Medicine, Morgantown, WV 26506, USA.
- Center for Neuroscience, West Virginia University, School of Medicine, Morgantown, WV 26506, USA; Department of Basic Pharmaceutical Sciences, West Virginia University, School of Pharmacy, Morgantown, WV 26506, USA.
- Center for Neuroscience, West Virginia University, School of Medicine, Morgantown, WV 26506, USA; Center for Health Restoration, West Virginia University, School of Nursing, Morgantown, WV 26506, USA.
Förderung
- NIGMS NIH HHS
Zitieren
APA
Turner, R. C., Naser, Z. J., Lucke-Wold, B. P., Logsdon, A. F., Vangilder, R. L., Matsumoto, R. R., Huber, J. D., & Rosen, C. L. (2017). Single low-dose lipopolysaccharide preconditioning: neuroprotective against axonal injury and modulates glial cells. Neuroimmunology and Neuroinflammation, 4(1), 6. https://doi.org/10.20517/2347-8659.2016.40
Vancouver
Turner RC, Naser ZJ, Lucke-Wold BP, Logsdon AF, Vangilder RL, Matsumoto RR, et al. Single low-dose lipopolysaccharide preconditioning: neuroprotective against axonal injury and modulates glial cells. Neuroimmunology and Neuroinflammation. 2017;4(1):6. doi:10.20517/2347-8659.2016.40
BibTeX
@article{Turner2017,
author = {Turner, Ryan C and Naser, Zachary J and Lucke-Wold, Brandon P and Logsdon, Aric F and Vangilder, Reyna L and Matsumoto, Rae R and Huber, Jason D and Rosen, Charles L},
title = {Single low-dose lipopolysaccharide preconditioning: neuroprotective against axonal injury and modulates glial cells},
journal = {Neuroimmunology and Neuroinflammation},
year = {2017},
volume = {4},
number = {1},
pages = {6},
doi = {10.20517/2347-8659.2016.40}
}
EUVIMED